GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubünden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuro’s web site).
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.
For more information, visit: www.geneuro.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006423/en/
Contact information
GeNeuro
Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com
NewCap (France)
Mathilde Bohin/Louis-Victor Delouvrier (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 94 98
geneuro@newcap.eu
RooneyPartners (US)
Jeanene Timberlake (media)
+1 646 770 8858
jtimberlake@rooneypartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Acquisition of ERIKS3.5.2024 16:07:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate has acquired ERIKS N.V., a specialized pan-European industrial components distributor and engineering service provider. Financial terms of the transaction were not disclosed. Founded in 1940, ERIKS has established itself as a European leader in specialized industrial services with over 200 locations in 12 countries. ERIKS’ deep industry experience, technical knowledge, local distribution network and dedicated engineering facilities allow it to develop advanced, customized solutions that drive performance improvements, deliver cost savings and add measurable technical and commercial value for its customers. Donald Quintin, Chief Executive Officer and Global President of Lone Star, said, "ERIKS represents an exciting investment opportunity and a valuable addition to our European investment portfolio. This acquisition aligns with our strategy of investing in market leading businesses that exhibit both growth and operating imp
Mars, Incorporated Enters Exclusive Discussions to Acquire the Entire Stake in French Veterinary Diagnostics Businesses Cerba Vet and ANTAGENE Held by the Cerba HealthCare Group3.5.2024 16:00:00 EEST | Press release
Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE. Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland. With approximately 140 Associates, Cerba Vet provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually. Headquartered in Lyon, France, ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests glo
Adtran and GLDS integrate Mosaic CP with BroadHub® for enhanced broadband service billing and management3.5.2024 15:00:00 EEST | Press release
Adtran today announced that GLDS’s customer management and billing platform, BroadHub®, is now integrated with Adtran’s Mosaic CP and its SDX Series of optical line terminals (OLTs). Building on a longstanding partnership, the collaboration enhances automated service management by enabling instantaneous adjustments to network conditions and rapid responses to customer demands. It promises to boost service capabilities and operational efficiencies for service providers globally, offering advanced scalability for growing networks and real-time data analytics for improved service management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503338277/en/ Adtran’s partnership with GLDS is helping service providers simplify customer management and streamline billing processes. (Photo: Business Wire) “Our strategic partnership with Adtran is driven by a shared commitment to empowering service providers with robust customer managem
Sampled Named One of the First Olink® Certified Service Providers3.5.2024 14:59:00 EEST | Press release
Sampled1 today announced that it has been named one of the first Olink® Certified Service Providers Olink’s state-of-the-art proteomics technology enables understanding of complex biological pathways and disease markers. Proteomics technology is an important tool for studying diseases, providing crucial insights into their underlying molecular mechanisms. The consistent and highly accurate results produced by Olink's Proximity Extension Assay (PEA) technology have made it widely recognized and extensively cited in various research fields for protein profiling and biomarker development. Olink® Certified Service Providers are recognized for their commitment to delivering the highest quality standards, undergoing rigorous training and annual certification using concordance samples. “We are proud to be one of the first Olink® Certified Service Providers and believe it highlights our dedication to pioneering health innovations. With this technology we can empower our clients with cutting-ed
KLDiscovery Takes Steps to Strengthen Balance Sheet and Long-Term Financial Foundation2.5.2024 23:30:00 EEST | Press release
KLDiscovery Inc. (“KLDiscovery” or the “Company”), a global leader in data management, information governance, eDiscovery, and advisory services solutions, today announced that it has reached an agreement in principle with its principal convertible debenture holders and its principal term loan lender to significantly reduce the Company’s long-term debt and strengthen its financial position, enabling KLDiscovery to focus on its growth model and drive investment in its market-leading client solutions. “Today’s announcement marks an important step forward for our company as we move into the future with a capital structure that supports our industry-leading team and long-term growth and profitability objectives,” said Chris Weiler, Chief Executive Officer of KLDiscovery. “KLDiscovery is a strong business with a leading market position, premier brands, and a clear vision for the future. This agreement underscores our key capital partners’ belief in that vision and will provide our company w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom